TScan Therapeutics公布Alloha™一期研究C组初步积极数据,评估Tsc-101在异基因造血细胞移植血癌患者中的疗效

美股速递
Jun 22

TScan Therapeutics近日公布了其正在进行的Alloha™一期临床试验中C组患者的初步积极数据。该研究旨在评估候选疗法Tsc-101在接受异基因造血细胞移植的血癌患者中的安全性与有效性。

初步结果显示,Tsc-101在这一患者群体中表现出令人鼓舞的临床活性与可管理的安全性特征。这些早期数据为后续开发提供了重要支持,表明该疗法在改善患者预后方面具有潜力。

公司将继续推进该项研究,并计划在未来分享更全面的临床结果。这一进展标志着TScan在针对血液恶性肿瘤的创新细胞疗法领域迈出了关键一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10